Mechanism of action of intestinal farnesoid X receptor in nonalcoholic fatty liver disease and related targeted drugs
10.3969/j.issn.1001-5256.2020.05.047
- VernacularTitle:肠道法尼醇X受体在非酒精性脂肪性肝病中的作用机制及相关靶向药物
- Author:
Kailing ZHANG
1
;
Liangping LI
Author Information
1. Department of Gastroenterology, Sichuan Provincial People’s Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China
- Publication Type:Research Article
- Keywords:
non-alcoholic fatty liver disease;
farnesol X receptor;
cholic acids
- From:
Journal of Clinical Hepatology
2020;36(5):1160-1163
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of nonalcoholic fatty liver disease (NAFLD) is gradually increasing in recent years, and the treatment of NAFLD is unsatisfactory due to the failure in lifestyle adjustment and a lack of effective drugs. Farnesoid X receptor (FXR), as the main bile acid receptor, may affect NAFLD by participating in glucose and fat metabolism, and intestinal FXR (iFXR) acts on the intestinal tract alone and may thus avoid the side effects of systemic release. Therefore, it may have potential value in the treatment of NAFLD, but there are also certain controversies. This article reviews the research advances in the role of iFXR in NAFLD.
